MAXCYTE, INC.

Share Issue/Capital Change • Mar 15, 2018

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 7489H

MaxCyte, Inc.

15 March 2018

MaxCyte, Inc.

("MaxCyte" or the "Company")

Notice of Full Year Results

Gaithersburg, Maryland - 15 March 2018: MaxCyte (LSE: MXCT, MXCR), a global cell-based medicines and life sciences company, will be announcing its full year audited results for the year ended 31 December 2017 on Wednesday 4 April 2018.  

Doug Doerfler, Chief Executive Officer, will host a presentation and live conference call for analysts at 11.00am BST on the day of the results at the offices of Panmure Gordon, One New Change, London, EC4M 9AF.

For further information, please contact:

MaxCyte Inc.
Doug Doerfler, Chief Executive Officer Ron Holtz, Chief Financial Officer	+1 301 944 1660
Nominated Adviser and Broker Panmure Gordon
Freddy Crossley (Corporate Finance) Ryan McCarthy Tom Salvesen (Corporate Broking)	+44 (0) 20 7886 2500
Financial PR Adviser Consilium Strategic Communications
Mary-Jane Elliott Chris Welsh Suki Virji	+44 (0)203 709 5700 [email protected]

About MaxCyte

MaxCyte (LSE: MXCT, MXCR) is a global cell-based medicines and life sciences company applying its patented cell engineering technology to help patients with high unmet medical needs in a broad range of conditions. MaxCyte is developing novel CARMA therapies for its own pipeline. CARMA is MaxCyte's mRNA-based proprietary platform for autologous cell therapy. In addition, through its core business, the Company leverages its Flow Electroporation® technology to enable its partners across the biopharmaceutical industry to advance the development of innovative medicines, particularly in cell therapy, including gene editing and immuno-oncology. The Company has placed its cutting-edge flow electroporation instruments worldwide, including with nine of the top ten global biopharmaceutical companies, and has more than 50 partnered programme licenses in cell therapy including more than 20 licensed for clinical use in cell therapy. With its robust delivery technology, MaxCyte helps its partners to unlock the full potential of their products.

For more information, visit http://www.maxcyte.com/.

This information is provided by RNS

The company news service from the London Stock Exchange

END

NORJIMATMBBBBBP